Supplemental chromium is a low-cost optional experiment for metabolic markers—especially long-term blood sugar and fasting insulin—mainly when insulin resistance or type 2 diabetes is already present. Benefits are usually modest; healthy adults rarely change. Safety at common study doses looks similar to placebo, with rare kidney-injury case reports at high or unclear exposures. No lifespan benefit is shown. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | ~70–90 mg/dL | Primary short-term glycemic response |
| HbA1c | ~4.8–5.2% | Multi-month average glucose exposure |
| Fasting insulin | ~2–6 µIU/mL | Detects hyperinsulinemia before glucose rises |
| HOMA-IR | <1.0–1.5 | Integrated insulin resistance index |
| Triglycerides | <100 mg/dL functional | Lipid domain sometimes responsive |
| HDL-C | >50–60 mg/dL | May rise modestly in some diabetes trials |
| Creatinine / eGFR | Creatinine in lab range; eGFR ≥90 preferred, ≥60 minimum for high-dose consideration | Renal safety |
| Urinalysis | Negative protein/blood | Early renal injury screen |
| Serum ferritin / iron studies | Age/sex-appropriate ferritin without deficiency or overload | Transferrin competition context |
Cadence: Baseline before high-dose or goal-directed use; reassess at about 8–12 weeks, then every 3–6 months if continued